Biosenic (XPAR:BIOS) FCF Margin %: 0.00% (As of Dec. 2024)


What is Biosenic FCF Margin %?

Biosenic XPAR:BIOS 9 FCF Margin % is 0.00% as of Dec. 2024. GuruFocus rates XPAR:BIOS with a GF Score™ of 9/100. The stock has 5 warning signs investors should review.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Biosenic's Free Cash Flow for the six months ended in Dec. 2024 was €-1.39 Mil. Biosenic's Revenue for the six months ended in Dec. 2024 was €0.00 Mil. Therefore, Biosenic's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

As of today, Biosenic's current FCF Yield % is -170.07%.

The historical rank and industry rank for Biosenic's FCF Margin % or its related term are showing as below:


During the past 12 years, the highest FCF Margin % of Biosenic was -1319.70%. The lowest was -27885.37%. And the median was -1617.50%.

XPAR:BIOS's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -84.65
* Ranked among companies with meaningful FCF Margin % only.

Biosenic FCF Margin % Related Terms

Biosenic FCF Margin % Historical Data

* Premium members only.

The historical data trend for Biosenic's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biosenic FCF Margin % Chart

Biosenic Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,617.50 0.00 0.00 0.00 0.00

Biosenic Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

XPAR:BIOS vs VRTX, REGN, ALNY: FCF Margin % Comparison

For the Biotechnology subindustry, Biosenic's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biosenic FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biosenic's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Biosenic's FCF Margin % falls into.


Biosenic FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Biosenic's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-2.221/0
= %

Biosenic's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-1.387/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Biosenic (XPAR:BIOS) has a FCF Margin % of 0.00% as of Dec. 2024. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Biosenic and its competitors.
Is Biosenic's FCF Margin % too high?
Biosenic's current FCF Margin % is 0.00%. Overall, Biosenic has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Biosenic's FCF Margin % compare to VRTX and REGN?
Biosenic's FCF Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Biosenic and its competitors. Biosenic's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biosenic stock overvalued right now?
Biosenic (XPAR:BIOS) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Biosenic's overall GF Score™ is 9/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Biosenic (XPAR:BIOS), the current FCF Margin % is 0.00% as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biosenic Business Description

Address Rue Granbonpre 11, Batiment H (bte 24), Mont-St-Guibert, BEL, 1435
Biosenic is engaged in the development of cell therapy products for orthopaedics and bone diseases. The product pipeline of the company includes; ALLOB for treatment of delayed-union fractures, spinal fusion procedures and revision spinal fusion, and PREOB. In addition, the firm is also focused on conducting preclinical research on next-generation product candidates such as combined cell-matrix products for large bone defects and maxillofacial applications.